Skip to Content
  • Previous Rank
    -
  • Revenue 3 Yr Annual Growth Rate
    147%
  • Revenue 3 Yr Growth Rank
    1
  • EPS 3 Yr Annual Growth Rate
    119%
  • EPS 3 Yr Growth Rank
    10
  • Total Return 3 Yr Annual Rate
    41%
  • Total Return 3 Yr Rank
    21

Investors buzz as medical-marijuana company’s oral THC solution, Syndros, is the only FDA-approved drug to treat nausea and vomiting caused by chemotherapy.

Company Information

Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.
Location
Chandler, Ariz.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
John Kapoor
Websitehttp://www.insysrx.com

Revenue, Net Income

Revenue Past Four Quarters ($M)$322
Net Income Past Four Quarters ($M)$53

Growth Rates and Ranks

Revenue 3 Yr Growth Rank1
EPS 3 Yr Annual Growth Rate119%
EPS 3 Yr Growth Rank10
Total Return 3 Yr Annual Rate41%
Total Return 3 Yr Rank
21